{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:33Z","timestamp":1740107433382,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","award":["IIT"],"award-info":[{"award-number":["IIT"]}],"id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00280-021-04395-y","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T16:02:52Z","timestamp":1660320172000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach"],"prefix":"10.1007","volume":"89","clinical-trial-number":[{"clinical-trial-number":"nct02841722","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Manon","family":"Reda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Macaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Bellio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Uwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ilie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Lorgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Rederstorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fumoleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"4395_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH et al (2012) Eribulin\u2014a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163\u2013184","journal-title":"Crit Rev Oncol Hematol"},{"key":"4395_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"4395_CR3","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1111\/ajco.12863","volume":"14","author":"Y Kikuchi","year":"2018","unstructured":"Kikuchi Y, Uchida Y, Shirakawa K et al (2018) A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol 14:e231\u2013e237","journal-title":"Asia Pac J Clin Oncol"},{"key":"4395_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00280-018-3567-y","volume":"81","author":"K Kimura","year":"2018","unstructured":"Kimura K, Iwamoto M, Tanaka S et al (2018) A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes. Cancer Chemother Pharmacol 81:923\u2013933","journal-title":"Cancer Chemother Pharmacol"},{"key":"4395_CR5","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4143\/crt.2017.446","volume":"50","author":"R Sabatier","year":"2018","unstructured":"Sabatier R, Di\u00e9ras V, Pivot X et al (2018) Safety results and analysis of eribulin efficacy according to previous microtubules-inhibitors sensitivity in the French prospective expanded access program for heavily pre-treated metastatic breast cancer. Cancer Res Treat 50:1226\u20131237","journal-title":"Cancer Res Treat"},{"key":"4395_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2016.12.017","volume":"32","author":"S Maeda","year":"2017","unstructured":"Maeda S, Saimura M, Minami S et al (2017) Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast 32:66\u201372","journal-title":"Breast"},{"key":"4395_CR7","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","volume":"15","author":"J Crawford","year":"2017","unstructured":"Crawford J, Becker PS, Armitage JO et al (2017) Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15:1520\u20131541","journal-title":"J Natl Compr Canc Netw"},{"key":"4395_CR8","doi-asserted-by":"publisher","first-page":"e000176","DOI":"10.1136\/esmoopen-2017-000176","volume":"2","author":"M Orditura","year":"2017","unstructured":"Orditura M, Gravina A, Riccardi F et al (2017) Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). ESMO Open 2:e000176","journal-title":"ESMO Open"},{"key":"4395_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clbc.2018.04.001","volume":"18","author":"KA Cadoo","year":"2018","unstructured":"Cadoo KA, Kaufman PA, Seidman AD et al (2018) Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by Eribulin Mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2-negative breast cancer. Clin Breast Cancer 18:433-440.e1","journal-title":"Clin Breast Cancer"},{"key":"4395_CR10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/0019-509X.200653","volume":"53","author":"J Bajpai","year":"2016","unstructured":"Bajpai J, Ramaswamy A, Gupta S et al (2016) Eribulin in heavily pretreated metastatic breast cancer: a tertiary care center experience from India. Indian J Cancer 53:460\u2013463","journal-title":"Indian J Cancer"},{"key":"4395_CR11","first-page":"14356","volume":"12","author":"P Macaire","year":"2020","unstructured":"Macaire P, Paris J, Vincent J et al (2020) Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: a population pharmacokinetic\/pharmacodynamic approach. Br J Clin Pharmacol 12:14356","journal-title":"Br J Clin Pharmacol"},{"key":"4395_CR12","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s11095-013-1099-z","volume":"30","author":"ML Pastor","year":"2013","unstructured":"Pastor ML, Laffont CM, Gladieff L et al (2013) Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients. Pharm Res 30:2795\u20132807","journal-title":"Pharm Res"},{"key":"4395_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bcp.12143","volume":"76","author":"JGC van Hasselt","year":"2013","unstructured":"van Hasselt JGC, Gupta A, Hussein Z et al (2013) Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia: eribulin mesilate-associated neutropenia. Br J Clin Pharmacol 76:412\u2013424","journal-title":"Br J Clin Pharmacol"},{"key":"4395_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. JCO 33:3199\u20133212","journal-title":"JCO"},{"key":"4395_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"4395_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/A:1005945218155","volume":"49","author":"G Frasci","year":"1998","unstructured":"Frasci G, Comella P, Aiuto G et al (1998) Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 49:13\u201326","journal-title":"Breast Cancer Res Treat"},{"key":"4395_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","volume":"31","author":"C Summers","year":"2010","unstructured":"Summers C, Rankin SM, Condliffe AM et al (2010) Neutrophil kinetics in health and disease. Trends Immunol 31:318\u2013324","journal-title":"Trends Immunol"},{"key":"4395_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00057-17","author":"SM Lawrence","year":"2018","unstructured":"Lawrence SM, Corriden R, Nizet V (2018) The ontogeny of a neutrophil: mechanisms of granulopoiesis and homeostasis. Microbiol Mol Biol Rev. https:\/\/doi.org\/10.1128\/MMBR.00057-17 (Epub ahead of print)","journal-title":"Microbiol Mol Biol Rev"},{"key":"4395_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/psp4.12345","volume":"7","author":"YK Cho","year":"2018","unstructured":"Cho YK, Irby DJ, Li J et al (2018) Pharmacokinetic-pharmacodynamic model of neutropenia in patients with myeloma receiving high-dose melphalan for autologous stem cell transplant. CPT Pharmacometrics Syst Pharmacol 7:748\u2013758","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4395_CR20","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1200\/JCO.2010.29.3597","volume":"28","author":"A Schmitt","year":"2010","unstructured":"Schmitt A, Gladieff L, Laffont CM et al (2010) Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. JCO 28:4568\u20134574","journal-title":"JCO"},{"key":"4395_CR21","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"4395_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"key":"4395_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/jcph.315","volume":"54","author":"O Majid","year":"2014","unstructured":"Majid O, Gupta A, Reyderman L et al (2014) Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. J Clin Pharmacol 54:1134\u20131143","journal-title":"J Clin Pharmacol"},{"key":"4395_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00280-012-1976-x","volume":"70","author":"LA Devriese","year":"2012","unstructured":"Devriese LA, Witteveen PO, Marchetti S et al (2012) Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol 70:823\u2013832","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T16:30:25Z","timestamp":1700929825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4395"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04395-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version is revised due to the update of new trial ID.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilles Freyer declares having to participate in a symposium organized by Eisai. All the other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Comit\u00e9 de Protection des Personnes Grand Est I (Approval Number CPP 2015\/14). Each patient provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Each patient provided written informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}